Oneness is committed to the development of new drug for the global unmet medical needs. With the global vision in innovation, we screen new drugs and initiate an in-depth exploration into the drug mechanism and pathology. The in-house research and development technology has been established to compete with international pharmaceutical companies and to maximize the value by our science and innovation.
Our culture is established on the basis of integrity to seek the truth. This is also a key foundation of our corporate governance, drug development, production, sales, and social responsibility. All of our employees work with a spirit of honesty and in compliance with regulations for an active implementation and promotion of the plans.
The biotech industry is featured with professionalism. In order to provide the investors with a better understanding of Oneness, we implemented transparency by holding an investor conference every quarter, providing response to questions on a daily basis and updating the ESG report annually. Oneness received an ESG rating by the MSCI in 2021 and scored the highest in product safety.
| Research Code | Therapeutic Area | Indication | Development Region | Pre-Clinical | Phase I | Phase II | Phase III | NDA | Market | More |
|---|---|---|---|---|---|---|---|---|---|---|
|
ON101
|
Dermatology | Diabetic Foot Ulcer |
1. Taiwan, Macau, Singapore, Malaysia, China & Indonesia
|
|
|
|
|
|
|
|
|
2.Southeast Asia
|
|
|
|
|
|
|||||
|
FB825
|
Dermatology, Immunology | Atopic Dermatitis, Allergic Asthma |
1. Taiwan
|
|
|
|
||||
|
2. US / Taiwan(SC formulation)
|
|
|
|
|||||||
|
FB704A
|
Immunology | Severe Asthma |
Taiwan
|
|
|
|
||||
|
SNS812
|
Infection | Pan-COVID |
US
|
|
|
|
||||
|
SNS851
|
Metabolism | Weight loss, Metabolism diseases |
Taiwan
|
|
